Driven by Our Promise.
CSL Behring is committed to developing novel therapies that save and improve the lives of patients with life-threatening diseases. As part of this commitment, we have established a Therapeutic Area that focuses on the #1 cause of death worldwide: Cardiovascular and Metabolic disease. Our goal is to address areas of high, unmet medical needs, and we strive to develop new approaches that will greatly improve how we treat these significant global health concerns.
To access a variety of educational resources and previous meeting materials visit the Cardiovascular and Metabolic events page at CSLBehringEvents.com
For more information on CSL Behring including our pipeline and ongoing clinical trials please visit CSLBehring.com or www.clinicaltrials.gov
ACC.22 Learning Pathways? (select all that apply) Ischemic Heart Disease